Purpose The purposes of this study were to estimate the incidence of chemotherapy-induced peripheral neuropathy (CIPN) and to identify its main determinants and impact in patient-reported outcomes. Methods We performed a prospective cohort study including 296 patients with incident breast cancer submitted to chemotherapy, followed for 1 year. Patients with incident CIPN were reevaluated 6 months after this diagnosis. Relative risks (RR) with 95 % confidence intervals (95 % CI) were computed to quantify the relation between different clinical characteristics and the occurrence of CIPN, using Poisson regression. The variation of patient-reported outcomes between baseline and 1-year follow-up assessments was compared between patients with and without CIPN. Results The cumulative incidence of CIPN in the first year after diagnosis was 28.7 % (95 % CI 23.8-34.1), and more than 80 % of the patients were still symptomatic after 6 months. Among the latter, there was a significant decrease in the median total neuropathy score, clinical version (7 versus 4) between the two periods. In multivariable analysis, the risk of CIPN was higher for treatment with docetaxel (cumulative doses ≤300 mg/m 2 , RR=6.96, 95 % CI 2.53-19.10; >300 mg/ m 2 , RR=13.32; 95 % CI 4.11-43.14). Alcohol consumption and diabetes were not significantly associated with CIPN. There were no significant differences in the variation of patient-reported outcomes between the baseline and 1-year follow-up evaluations. Conclusions CIPN was frequent in this contemporary cohort of early-stage breast cancer patients and was strongly associated with docetaxel-based regimens. Symptoms persisted for at least 6 months in most patients, but severity was low and CIPN had no impact on patient-reported outcomes.
Introduction
Breast cancer is the most frequent cancer in women, with an estimated 1.7 million new cases diagnosed in 2012 [1] and is among those with better survival (the 5-year relative survival is higher than 80 % in most developed countries [2, 3] ). The growing number of women living for increasingly long periods after the diagnosis of breast cancer highlights the need of a comprehensive assessment of the burden of the disease related with breast cancer treatments among survivors. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent adverse effects of many commonly used chemotherapeutic agents [4] , with potential impact on the patients' quality of life (QoL) [5, 6] .
CIPN involve the peripheral nervous system and lead to predominantly sensory peripheral neuropathy, with a Bstocking and glove^distribution characterized by sensory loss, paresthesia, numbness, and tingling, that may be aggravated by neuropathic pain [7, 8] . Treatments associated with a higher incidence of CIPN include those with platinum drugs, vinca alkaloids, or taxanes [9] . The estimated occurrence of CIPN among patients undergoing chemotherapy varied widely across previous investigations, largely reflecting differences in study designs, populations studied, specificities of the treatment schemes, and lack of uniformity in CIPN assessment methods [10] [11] [12] [13] [14] .
Preexisting peripheral neuropathies, namely due to diabetes or excessive alcohol consumption have been considered risk factor for CIPN. Although these associations seem plausible, because such conditions can cause a neuropathy similar to CIPN, their role as risk factors for CIPN is not yet demonstrated since most previous investigations excluded these patients and the few existing studies have conflicting results [15] [16] [17] [18] and, to our knowledge, the available results do not refer specifically to breast cancer patients.
A prospective study with a systematic neurological evaluation of patients during different moments of the first year after breast cancer diagnosis, and a standardized clinical assessment and characterization of CIPN among patients in early stages, treated with different chemotherapy schemes, may contribute to a better understanding of the burden of this neurological complication. Therefore, we aimed to estimate CIPN incidence and to identify its main determinants and impact in different patient-reported outcomes.
Methods

Study design and participants
We conducted a prospective cohort study of women consecutively recruited in 2012 among those with newly diagnosed breast cancer admitted to the Breast Clinic of the Portuguese Institute of Oncology of Porto, Portugal. The study methods have been described in detail elsewhere [19] . Briefly, we consecutively selected women proposed for surgery, either as primary treatment or after neoadjuvant chemotherapy, whose follow-up would go on to occur in the same hospital. We excluded those previously treated for cancer, submitted to breast surgery, with stage IV breast cancer, and those scoring less than 17, or less than 16 for women over 65 years old in the Montreal Cognitive Assessment (MoCA), which was assumed to correspond to a high probability of cognitive impairment [20] .
The cohort included 502 patients with incident breast cancer, from whom 296 (59.0 %) underwent neoadjuvant or adjuvant chemotherapy in the first year after diagnosis and therefore were considered for the present analysis.
Data collection
All patients underwent a neurological evaluation and sociodemographic and medical data were collected at baseline (before any treatment), 2 weeks after surgery, 3 weeks after the last cycle of chemotherapy, and 1 year after enrolment. Patients diagnosed with CIPN during the first year of follow-up were also evaluated at the moment of CIPN confirmation and after 6 months, in order to define the chronicity of such condition.
At baseline, information on the consumption of alcoholic beverages and previous diagnosis of diabetes or thyroid pathology was obtained from the patients and/or review of their medical records. Self-report or record of either a previous diagnosis or treatment with insulin or oral antidiabetic drugs were considered to classify patients as having diabetes. Individuals drinking at least one alcoholic drink per month were classified as current drinkers and those who stopped drinking at least 6 months before the interview as former drinkers. Current drinkers were further classified according to the amount of ethanol consumed; for this purpose, we considered that a standard drink corresponds to 14 g of ethanol.
Preexisting cases of peripheral neuropathy were identified at the baseline neurological assessment. During the remaining evaluations, data about breast cancer stage, surgery, chemotherapy (including chemotherapy schemes and total dose delivered), and other adjuvant treatments performed were collected from clinical records by clinicians.
Patient-reported outcomes were evaluated before any treatment and at 1 year after enrolment. QoL was assessed using the self-administered questionnaire of the European Organization for the Research and Treatment of Cancer (EORTC) (QLQ-C30) [21] ; the specific global health status/QoL subscale was used for the purpose of this study. Sleep quality was evaluated using the Pittsburg Sleep Quality Index (PSQI) [22] . Anxiety and depression were evaluated using the Hospital Anxiety and Depression Scale (HADS) [23] . For the global health status/QoL subscale, higher scores represent a healthier level of QoL, while in the remaining instruments, higher scores correspond to worse outcomes.
Outcome definition
CIPN was defined as peripheral neuropathy beginning after chemotherapy; among patients with preexisting peripheral neuropathy, CIPN was considered to have occurred only if there was a worsening of neuropathy after the beginning of chemotherapy. CIPN was quantified using the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) [24] and the Total Neuropathy Score, clinical version (TNSc) [25] . The latter requires that strength, deep tendon reflexes, vibration sensibility (128-Hz tuning fork), and pain sensation (wood cocktail-stick) are evaluated to quantify the severity of neuropathy. The classification system proposed by the International Association for the Study of Pain (IASP) was used in order to classify painful CIPN [26] .
Incident cases of CIPN were identified through referral by any member of the clinical team or during the systematic neurological evaluations performed by neurologists. Cases identified at the time of the scheduled follow-up evaluations were assigned an estimated date of onset based on information provided by the patients. When applicable, information regarding chemotherapy interruption or dose reduction was retrieved from records.
Statistical analysis
We computed cumulative incidence estimates for CIPN at the 1-year follow-up and the corresponding 95 % confidence intervals (95 % CI).
Crude and adjusted relative risks (RR) and corresponding 95 % CI for the relation between different characteristics of the patients and the occurrence of CIPN in the first year after enrolment were computed using Poisson regression; variables included in each model are described in the footnotes of the corresponding table.
Standardized scores (z scores) of the variation in patientreported outcomes between the baseline assessment and the 1-year follow-up evaluation were computed.
Statistical analysis was conducted using STATA®, version 11.2 (StataCorp, College Station, TX, USA).
Results
Figure 1 depicts the number of patients in each evaluation performed. From those who underwent chemotherapy, one patient abandoned the study (no reason specified), and 295 (99.7 %) completed the 1-year follow-up evaluation. A total of 85 patients were diagnosed with CIPN and all completed the 6-month evaluation after diagnosis.
Patients' characteristics
The main demographic and medical characteristics of the participants are presented in Table 1 . In addition to chemotherapy, endocrine therapy and radiotherapy were the most common adjuvant treatments (83.7 and 83.4 %, respectively).
Incidence and characterization of CIPN
During the first year after the diagnosis of breast cancer, 28.7 % (95 % CI 23.8-34.1) of the patients were diagnosed with CIPN. Among those submitted to docetaxel-based regimens, the cumulative incidence was 38.0 % (95 % CI 31.8-44.7). The median [percentile 25-percentile 75 (P25-P75)] time to CIPN onset since the beginning of chemotherapy was 107 (84-122) days.
At the moment of CIPN diagnosis, all patients presented peripheral sensory neuropathy grade 1 or 2 but only 18.8 % had motor neuropathy (grade 1 to 3), according to the CTCAE v4.0; the TNSc ranged between 3 and 12 ( Predictors of CIPN during the first year of follow-up Diabetes and alcohol consumption habits at baseline were not significantly associated with the occurrence of CIPN (Table 3) , and the RR estimates for the relation between docetaxel-based chemotherapy and CIPN did not change meaningfully when further adjusted for diabetes or alcohol consumption (7.22 vs. 7.09).
Impact of CIPN in patient-reported outcomes at 1-year follow-up
The variation of z scores of patient-reported health-related outcomes, between the baseline and the 1-year follow-up assessment, according to the presence of CIPN is represented in Fig. 2 . There were no statistically significant differences in the variation between the two moments of evaluation according to the presence of CIPN. Also, there were no statistically significant differences in the variation of any of the patient reported outcomes according to the presence of motor neuropathy or the severity of CIPN (data not shown).
CIPN during the 6-month follow-up of CIPN patients
A total of 70 (82.4 %, 95 % CI 72.8-89.1) of all patients with CIPN remained symptomatic to the end of the follow-up of the subcohort.
As depicted in Table 2 , among those symptomatic at the 6-month follow-up, there was a decrease in the severity of motor (present in 18.6 and 7.1 % of the patients at baseline and follow-up, respectively; P=0.057) and sensory symptoms (grade 2 in 38.6 and 21.4 % of the patients at baseline and follow-up, respectively; P=0.017) during the follow-up. The The following terms are defined: ALND, axillary lymph node dissection; DC, four cycles of concomitant doxorubicin (60 mg/m One patient that performed paclitaxel was excluded median (P25-P75) TNSc decreased significantly from 7 (5-9) to 4 (2-6).
In crude and multivariate analyses, sociodemographic and medical characteristics (including breast cancer treatments) and patient-reported outcomes at baseline were not associated with higher risk of CIPN after 6 months of the diagnosis of this complication (data not shown).
Discussion
The present study provides a comprehensive assessment of the clinical epidemiology of CIPN after neoadjuvant and adjuvant treatments of breast cancer, in a contemporary cohort of women with early-stage cancer. Important strengths of this investigation are the nearly complete follow-up of the main cohort and a complete follow-up of the CIPN patients. Furthermore, the use of the TNSc to grade CIPN has the advantage of including an objective nerve function examination [25, 27] . Peripheral neuropathy is a major complication of both diabetes and alcoholism and both have been assumed in the literature as risk factors for CIPN [28, 29] . To our knowledge, this is the first prospective study addressing diabetes and alcohol consumption as risk factors for CIPN in breast cancer patients. However, we did not find a significant association between these two exposures and CIPN or its severity (data not shown). These results suggest that alcohol consumption and diabetes have no important effect in the occurrence of CIPN, at least among patients with relatively low alcohol intake and type 2 controlled diabetes mellitus, such as those in the present cohort. Unfortunately, it was not possible to assess the effect of previous neuropathy in the occurrence of CIPN because the number of patients with neuropathy at baseline was too small. There were only two patients with mild diabetic neuropathy diagnosed at baseline, and these were not treated with docetaxel.
Nearly 30 % of the patients developed CIPN within 1 year of breast cancer diagnosis, and the cumulative incidence of docetaxel-induced peripheral neuropathy was 38.0 %. Our data yielded estimates of the frequency of docetaxel-induced peripheral neuropathy similar to those found by other authors in Denmark [30, 31] , but in our cohort all women with CIPN had sensory symptoms up to grade 2, whereas in the former investigations, the proportion of cases graded higher than 2 was 7.7 % [31] and 32.5 % [30] . However, one of these studies excluded women with sensory neuropathy grade 1 and relied on self-reports to define CIPN [30] , the other identified and characterized CIPN using retrospective clinical record data [31] , and both used version 2.0 of the CTCAE to assess the severity of CIPN. Regarding motor symptoms, its occurrence has been described to be less frequent than sensory neuropathy [4, 32] , which was in accordance with our results.
Higher doses per cycle [30] and cumulative doses over 600 mg/m 2 [28] have been described as risk factors for docetaxel-induced peripheral neuropathy, though a more recent study, with patients that underwent cumulative doses less than 450 mg/m 2 , did not find a dose-response relationship [30] . In our cohort, compared to chemotherapy schemes with no docetaxel, patients treated with a cumulative dose of docetaxel ≤300 mg/m 2 had a nearly sevenfold higher risk of CIPN, and the RR was just over 13 times higher for those receiving >300 mg/m 2 . Unfortunately, the present study does not allow an assessment of the impact of dose-dense regimens in the incidence of CIPN since the use of this treatment strategy in the institution where patients were recruited started approximately 2 years after the baseline assessment.
A systematic review addressing the role of CIPN on QoL among cancer patients found a probable negative association with QoL [33] . Of the 11 studies assessing the association of CIPN on patients' QoL, three did not find an association and the others concluded that CIPN was associated with a lower QoL. However, none of the studies included specifically women with breast cancer. A recent study in early breast cancer patients that underwent chemotherapy with docetaxel found that the persistence of CIPN 1-3 years after treatment had a significant negative correlation with health-related QoL [6] . In our study, we did not find a significant impact of CIPN in patient-reported outcomes at 1-year of followup, which can be related with the lower severity of docetaxel CIPN and the fact that patients improved over this period.
Despite the contribution of the present study to an accurate characterization of the occurrence of CIPN among early-stage breast cancer patients, some limitations need to be addressed. Although nerve conduction studies (NCS) are considered the goal standard for CIPN diagnosis, the previous prospective studies using these methods to evaluate CIPN in breast cancer patients receiving chemotherapy with taxanes included a small number of breast cancer patients [34] [35] [36] , reflecting the fact that NCS are time and resource consuming. Our study was based on a cohort of a large number of participants, assembled and followed in a clinical setting, which precludes complex evaluations such as NCS. Nevertheless, it is important to emphasize that we assessed CIPN using the TNSc, which incorporates not only subjective but also objective items [25, 27] . A recent article from the chemotherapy-induced peripheral neuropathy outcome measure standardization study (CI-PeriNomS) concluded that vibratory sensation and light touch are associated with abnormal sural nerve amplitudes, suggesting that these components of neurological exam are reliable indicators of CIPN [37] ; these two measures are included in TNSc score used in our study. We excluded patients with stage IV and those not submitted to surgical treatment, which limits the generalization to patients with more advanced disease. Furthermore, all patients were selected from the same institution, the Portuguese Institute of Oncology of Porto. However, this is the largest hospital providing care to oncological patients in the north of Portugal, treating patients from a wide geographical area, which may help to mitigate the latter limitation. Previous studies have shown that subclinical deficits in sensory function may be present among patients with colorectal cancer [38, 39] and myeloma [40, 41] even before initiating any therapy, and CIPN may correspond to an exacerbation of this preexisting condition. In our study, although all patients underwent a neurological examination before breast cancer treatment, to exclude clinical neuropathy, we did not perform quantitative sensory testing, and therefore, we cannot exclude the presence of subclinical deficits in sensory function before treatments. Future studies should address the role of these preexisting conditions as an effect modifier of the association between chemotherapy and CIPN. The participants in our study were followed for 6 months after the diagnosis of CIPN, and a longer follow-up will allow the comparison with studies with longer follow-up [42] . Previous studies addressed the effect of interventions to prevent CIPN [43] [44] [45] , but no such exposures were observed in our cohort.
In conclusion, CIPN was frequent in this prospective cohort study of early-stage breast cancer patients and was strongly associated with docetaxel-based regimens. Symptoms persisted for at least 6 months in most patients, but severity was usually low; painful CIPN, and dose reduction due to CIPN were observed in a small number of patients, and CIPN had no impact on patient-reported outcomes. The results from this study are useful to support clinical decisions related with the use of docetaxel-based chemotherapy.
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